VR Adviser, LLC
Annual return '25
+10.0%
SPY '25
+17.7%
Alpha
-7.7ptsvs SPY
Invested
$2.7B
Holdings
33
Trades YTD
0
Performance · Fund vs SPY
Cumulative return · quarterly snapshotsCoverage 99%. 4 quarters of 2025 measured against SPY adj-close benchmark.
Top holdings · current snapshot
Source: 13F-HR01
$APGE
APOGEE THERAPEUTICS INC
Q4 2024: New position (8.49M shares)
26.7%
02
$ERAS
ERASCA INC
Q2 2025: Increased +10.1% (16.22M → 17.86M shares)
9.9%
03
$ORKA
ORUKA THERAPEUTICS INC
Q1 2025: Increased +26.3% (3.29M → 4.15M shares)
7.6%
04
$SYRE
SPYRE THERAPEUTICS INC
Q4 2024: New position (2.69M shares)
6.9%
05
$KALV
KALVISTA PHARMACEUTICALS INC
Q1 2025: Increased +7.3% (6.25M → 6.70M shares)
4.9%
06
$DNTH
DIANTHUS THERAPEUTICS INC
Q3 2025: Sold 3.9% (1.00M → 960.8k shares)
3.7%
07
$DMRA
DAMORA THERAPEUTICS INC
Held since at least Q1 2024
3.5%
08
$OCUL
OCULAR THERAPEUTIX INC
Q3 2025: Increased +3.1% (12.76M → 13.16M shares)
3.3%
09
$COGT
COGENT BIOSCIENCES INC
Q3 2025: Sold 15.9% (4.76M → 4.00M shares)
2.9%
10
$VRDN
VIRIDIAN THERAPEUTICS INC
Q4 2024: New position (3.88M shares)
2.8%
Recent trades · Last 90 days
No Form 4 / 13D / 13G trade events on file in the recent window. 13F filers report position snapshots quarterly rather than per-trade events, so this section is most useful for managers who also file Form 4 or 13D/G.
Convergence · Pattern Engine ships in v1.1
30-day windowIn development
Convergence participation lands with the Pattern Engine.
Once the Pattern Engine ships, this section will list every active convergence event this fund is named in — with the other named funds, the Congress members on the same name, and combined position size.
Source data: SEC EDGAR · 13F-HR filings · Performance through 2025-12-31 · Last refreshed 09:26 UTC.